Business
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The race toward a COVID-19 vaccine is focused around scientific development right now, but companies also need to be planning for manufacturing.
Numerous biopharma companies are testing or working to develop drugs and vaccines. But what is a bit unusual is the number of staffers at biotech and pharma companies and health care involved as participants in studies and clinical trials.
Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round. The round was led by Frazier Healthcare Partners with participation from Alta Partners and Longwood Fund.
Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
Researchers at the University of Maryland School of Medicine evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Neurocrine Biosciences is partnering with Japan’s Takeda Pharmaceutical to develop and commercialize molecules in Takeda’s early-to-mid-stage psychiatry pipeline.
Sanofi announced plans to increase its vaccines research and production capabilities. As part of the plan it will invest $679.4 million (€610 million) to create a new production site and a research center, both in France.
The two companies will explore potential oncology treatments with emerging technology.
The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.